State Administration for Market Regulation, Anti-Monopoly Guidelines for the Pharmaceuticals Sector (Draft for Comments)

国家市场监督管理总局关于药品领域的反垄断指南 (征求意见稿)

August 26, 2024 | BY

Susan Mok

SAMR prohibits monopoly agreements that fix or modify pharmaceutical prices.

Issued: August 9, 2024

Main contents:  Fixing or Modifying Pharmaceutical Prices

Pharmaceutical business operators that are competitors are forbidden from entering into the following monopoly agreements concerning the fixing or modification of pharmaceutical prices:

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]